Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
BMC Cancer
|
August 9, 2025
Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB)
Robert Olson, Marjorie Cua, Quinn Matthews, et al.
Practical Radiation Oncology
|
September 20, 2024
Effect of Treatment Delivery Schedule for Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy: A Population-Based Analysis
John Paul Abrina, Sarah Baker, Ella Mae Cruz-Lim, et al.
Brachytherapy
|
June 26, 2012
Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program
Mira Keyes, William James Morris, Ingrid Spadinger, et al.
BMC Cancer
|
October 30, 2019
SUPR-3D: A randomized phase iii trial comparing simple unplanned palliative radiotherapy versus 3d conformal radiotherapy for patients with bone metastases: study protocol
Robert Olson, Roel Schlijper, Nick Chng, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 24, 2026
Treatment With Stereotactic Ablative Radiotherapy for patients with Up to 5 Oligometastatic cancer lesions: Long-Term Outcomes of the Nonrandomized Population-Based Phase 2 SABR-5 Clinical Trial
Curtis Leclerc, Sarah Baker, Will Jiang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 15, 2022
Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial
Sarah Baker, Benjamin Mou, Will Jiang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 6, 2022
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial
Sarah Baker, Will Jiang, Benjamin Mou, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 9, 2025
The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial
Sarah Baker, Curtis Leclerc, Hanna Atmanspacher-Wirth, et al.
BMC Cancer
|
October 6, 2018
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
Robert Olson, Mitchell Liu, Alanah Bergman, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 15, 2022
Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial
Matthew Van Oirschot, Alanah Bergman, Wilko F A R Verbakel, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
BMC Cancer
|
August 9, 2025
Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB)
Robert Olson, Marjorie Cua, Quinn Matthews, et al.
Practical Radiation Oncology
|
September 20, 2024
Effect of Treatment Delivery Schedule for Patients With Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy: A Population-Based Analysis
John Paul Abrina, Sarah Baker, Ella Mae Cruz-Lim, et al.
Brachytherapy
|
June 26, 2012
Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program
Mira Keyes, William James Morris, Ingrid Spadinger, et al.
BMC Cancer
|
October 30, 2019
SUPR-3D: A randomized phase iii trial comparing simple unplanned palliative radiotherapy versus 3d conformal radiotherapy for patients with bone metastases: study protocol
Robert Olson, Roel Schlijper, Nick Chng, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 24, 2026
Treatment With Stereotactic Ablative Radiotherapy for patients with Up to 5 Oligometastatic cancer lesions: Long-Term Outcomes of the Nonrandomized Population-Based Phase 2 SABR-5 Clinical Trial
Curtis Leclerc, Sarah Baker, Will Jiang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 15, 2022
Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial
Sarah Baker, Benjamin Mou, Will Jiang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 6, 2022
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial
Sarah Baker, Will Jiang, Benjamin Mou, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 9, 2025
The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial
Sarah Baker, Curtis Leclerc, Hanna Atmanspacher-Wirth, et al.
BMC Cancer
|
October 6, 2018
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
Robert Olson, Mitchell Liu, Alanah Bergman, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 15, 2022
Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial
Matthew Van Oirschot, Alanah Bergman, Wilko F A R Verbakel, et al.
Page
of 3